ESMO 2023: RENOTORCH Assesses Toripalimab and Axitinib in RCC

A roundtable discussion, moderated by Brian Rini, MD, addressed considerations for clear versus nonclear cell kidney cancer, as well as recent data from ESMO 2023. Dr. Rini was joined by Tian Zhang, MD; David McDermott, MD; and Hans Hammers, MD.

In the next segment of the roundtable series, the panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for clear cell RCC.

Видео ESMO 2023: RENOTORCH Assesses Toripalimab and Axitinib in RCC канала GU Oncology Now